|
|
|
|
|
Omalizumab
drug data and news
Omalizumab drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Omalizumab | ||
| Brand Names/Synonyms | Ig gamma-1 chain C region; Xolair (Genentech Inc) | ||
| Indication | For treatment of asthma caused by allergies | ||
| Sponsored links | Description | A recombinant DNA-derived humanized IgG1ï?« monoclonal antibody that selectively binds to human immunoglobulin E (IgE). Xolair is produced by a Chinese hamster ovary cell suspension culture in a nutrient medium containing the antibiotic gentamicin. | |
| Pharmacology | Xolair inhibits the binding of IgE to the high-affinity IgE receptor (FceRI) on the surface of mast cells and basophils. Reduction in surface-bound IgE on FceRI-bearing cells limits the degree of release of mediators of the allergic response. Xolair is used to treat severe, persisten asthma. | ||
| Mechanism Of Action | Xolair binds to IgE (a class of antibodies normally secreted in allergic responses), which prevents their binding to mast cells and basophils. | ||
| Omalizumab News (When available) |
Tanox Reports 2006 First Quarter Results May 2, 2006 New drug offers relief for those with allergic asthma May 10, 2006 Allergic asthma May 10, 2006 The facts about asthma May 2, 2006 Tanox Reports 48-Week Results From TNX-355 Phase 2 Clinical Trial May 2, 2006 (PRN) Tanox to Present at Two Investor Conferences in May Apr 17, 2006 Fibrogen, Astellas Anemia Deal: $300M, Plus $465M In Milestones Apr 28, 2006 | ||
| Dosage Forms | POWDER FOR SOLUTION | ||
| Drug_Category | Immunomodulatory Agents; Anti-Asthmatic Agents; unclassified therapeutic agents (92:00.00) | ||
| Absorption | Not Available | ||
| Interactions | Not Available | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | Humanized anti-IgE antibody | ||
| Chemical Formula | C6450H9916N1714O2023S38 >Anti IgE antibody VL domain chain 1 >Anti IgE antibody VH domain chain 2 >Anti IgE antibody VL domain chain 2 | ||
| Molecular Weight | 145058.2 | ||
| Smiles String | Not Available | ||
| Melting Point | 61 oC (FAB fragment), 71 oC (whole mAb) - Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000). | ||
| Water Solubility | Not Available | ||
| State | Transparent, slightly viscous, aqueous liquid | ||
| LogP/Hphobicity | -0.432 | ||
| Isoelectric Point | 7.03 | ||
| Biotransformation | Most likely removed by opsonization via the reticuloendothelial system. | ||
| Half Life | 26 days | ||
| Protein Binding [%] | Not Available | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Omalizumab.html http://www.rxlist.com/cgi/generic3/xolair.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | BIOD00081 | ||
| CAS Registry Number | 242138-07-4 | ||
| KEGG Compound ID | Not Available | ||
| PubChem ID | Not Available | ||
| PharmGKB ID | PA10374 | ||
| SwissProt ID | IGHG1_HUMAN (P01857) | ||
| GenBank ID | J00228 | ||
| Drug ID Number [DIN] | 2260565 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |